Compound · clinical trials

Chidamide clinical trials

Also listed in trial records as HBI-8000, HDACi, Epidaza, CS055

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 62 trials in our China, Taiwan, UK, USA, Germany, France, Spain, Italy, Belgium, Austria, Czechia, Brazil, Japan, South Korea, Singapore and Australia registers that name Chidamide as an intervention. Synced 10 Nov 2026

62Current trials

47Recruiting now

36Lead sponsors

16Country registers

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Synced 10 Nov 2026 · Editorial standards

At a glance

Chidamide is named as an intervention in 62 current clinical trials in our China, Taiwan, UK, USA, Germany, France, Spain, Italy, Belgium, Austria, Czechia, Brazil, Japan, South Korea, Singapore and Australia registers. 47 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Chinese PLA General Hospital (6). The most-studied condition is Peripheral T Cell Lymphoma.

Patient leaflets for Chidamide

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

UK
United Kingdom: Search MHRA Products
Patient information leaflets and SmPCs for UK-licensed products.
US
United States: Search DailyMed
FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Trials by status

Recruiting4776%
Not yet open915%
Active, closed46%
By invitation23%

Trials by phase

Phase 23963%
Phase 1/2915%
Phase 3813%
Not applicable23%
Early Phase 112%
Observational12%
Phase 112%
Phase 2/312%

Clinical trials of Chidamide

62 trials

Study	Phase	Status	Lead sponsor	Registers
SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma NCT06122389 · ClinicalTrials.gov ↗ · Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy	Phase 3	Recruiting	Jiangsu HengRui Medicine Co., Ltd	China
A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients NCT06497985 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 3	Recruiting	Chipscreen Biosciences, Ltd	China
A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19) NCT07234162 · ClinicalTrials.gov ↗ · Peripheral T-cell Lymphoma	Phase 3	Recruiting	Dizal Pharmaceuticals	China, Taiwan
Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP NCT07493109 · ClinicalTrials.gov ↗ · Diffuse Large B-Cell Lymphoma (DLBCL)	Phase 3	Recruiting	Ou Bai, MD/PHD	China
Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia NCT07514936 · ClinicalTrials.gov ↗ · Newly Diagnosed Acute Myeloid Leukemia (AML), Elderly Patients	Phase 3	Recruiting	Chinese PLA General Hospital	China
Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen NCT05088226 · ClinicalTrials.gov ↗ · Peripheral Blood Stem Cell Transplantation	Phase 2	Recruiting	Chinese PLA General Hospital	China
Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia NCT05566054 · ClinicalTrials.gov ↗ · Acute Monocytic Leukemia, Newly Diagnosed	Phase 2	Recruiting	The First Affiliated Hospital of Soochow University	China
Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL) NCT05833724 · ClinicalTrials.gov ↗ · Relapsed or Refractory Peripheral T-cell Lymphoma	Phase 2	Recruiting	Great Novel Therapeutics Biotech & Medicals Corporation	Taiwan
Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia NCT05881265 · ClinicalTrials.gov ↗ · APL	Phase 2	Recruiting	Shanghai Jiao Tong University School of Medicine	China
Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma NCT05958719 · Peripheral T Cell Lymphoma, Epigenetic Repression	Phase 2	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer NCT05983107 · ClinicalTrials.gov ↗ · HR+/HER2- Advanced Breast Cancer, Targeted Therapy	Phase 2	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia NCT06084819 · ClinicalTrials.gov ↗ · Relapsed/Refractory Acute Myeloid Leukemia	Phase 2	Recruiting	Chinese PLA General Hospital	China
Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma NCT06151106 · ClinicalTrials.gov ↗ · Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Refractory T-Cell Lymphoma	Phase 2	Recruiting	The First Affiliated Hospital of Xiamen University	China
Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma NCT06158386 · ClinicalTrials.gov ↗ · Follicular Lymphoma, Refractory B-Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma	Phase 2	Recruiting	The First Affiliated Hospital of Xiamen University	China
VAC Regimen for AML Patients Who Failed to Response to VA Regimen NCT06220162 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase 2	Recruiting	The First Affiliated Hospital of Soochow University	China
Chidamide Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant. NCT06393361 · Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma	Phase 2	Recruiting	Chinese PLA General Hospital	China
Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML NCT06451861 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase 2	Recruiting	Guangdong Provincial People's Hospital	China
Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL NCT06570447 · ClinicalTrials.gov ↗ · Diffuse Large B-Cell Lymphoma-Recurrent, Diffuse Large B-Cell Lymphoma-Refractory	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer NCT06685276 · ClinicalTrials.gov ↗ · Colorectal Cancer Metastatic	Phase 2	Recruiting	Dai, Guanghai	China
HDAC Inhibitor Combination With Chemoimmunotherapy in the Neoadjuvant Treatment of pMMR Locally Advanced Colon Cancer NCT06709885 · ClinicalTrials.gov ↗ · Colon Adenocarcinoma	Phase 2	Recruiting	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University	China
Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion NCT06739395 · ClinicalTrials.gov ↗ · Solid Tumor, Precision Medicine	Phase 2	Recruiting	Tianjin Medical University Second Hospital	China
Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients With DLBCL Intolerant to Chemotherapy NCT06758037 · ClinicalTrials.gov ↗ · DLBCL, Diffuse Large B-Cell Lymphoma	Phase 2	Recruiting	First Affiliated Hospital of Ningbo University	China
Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes NCT06891157 · ClinicalTrials.gov ↗ · Chidamide, R-CHOP Chemotherapy, DLBCL - Diffuse Large B Cell Lymphoma	Phase 2	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients NCT06928376 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, First Line Therapy	Phase 2	Recruiting	Chinese PLA General Hospital	China
QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer NCT06951997 · ClinicalTrials.gov ↗ · Metastatic Pancreatic Cancer	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide in Refractory MSS Metastatic Colorectal Cancer NCT06979908 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer	Phase 2	Recruiting	The First Hospital of Jilin University	China
Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients NCT07159620 · ClinicalTrials.gov ↗ · Adult T-cell Leukemia/Lymphoma	Phase 2	Recruiting	The First Affiliated Hospital of Soochow University	China
Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AML NCT07304232 · ClinicalTrials.gov ↗ · Allogeneic Hematopoietic Cell Transplantation (HCT), AML (Acute Myeloid Leukemia)	Phase 2	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children NCT07318831 · ClinicalTrials.gov ↗ · Neuroblastoma (NB), Neuroblastoma in Children	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL NCT07380984 · ClinicalTrials.gov ↗ · Natural Killer/T-cell Lymphoma	Phase 2	Recruiting	Ruijin Hospital	China
CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL NCT07397832 · ClinicalTrials.gov ↗ · Diffuse Large B-Cell Lymphoma (DLBCL)	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) Expression NCT07412262 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 2	Recruiting	Guangdong Association of Clinical Trials	China
Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL NCT07493148 · ClinicalTrials.gov ↗ · Diffuse Large B-Cell Lymphoma (DLBCL)	Phase 2	Recruiting	Ou Bai, MD/PHD	China
Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission NCT07507318 · ClinicalTrials.gov ↗ · Diffuse Large B-Cell Lymphoma	Phase 2	Recruiting	Rong Tao	China
Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocrine Carcinoma NCT07518602 · ClinicalTrials.gov ↗ · Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)	Phase 2	Recruiting	Sun Yat-sen University	China
Chidamide, Lenalidomide, and Rituximab in Newly Diagnosed Elderly/unFit DE-DLBCL NCT07884708 · ClinicalTrials.gov ↗ · Double Expressor DLBCL, ELDERLY PEOPLE, Unfit, New-diagnosis DLBCL	Phase 2	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients NCT04025450 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 1/2	Recruiting	The First Affiliated Hospital of Soochow University	China
Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse NCT05270200 · ClinicalTrials.gov ↗ · Leukemia, Myeloid, Acute	Phase 1/2	Recruiting	Zhujiang Hospital	China
Genotype-guided Treatment in Newly Diagnosed PTCL NCT05675813 · ClinicalTrials.gov ↗ · Peripheral T Cell Lymphoma	Phase 1/2	Recruiting	Ruijin Hospital	China
Chidamide Prevents Recurrence of High-risk AML After Allo-HSCT NCT05682755 · ClinicalTrials.gov ↗ · Leukemia, Myeloid, Acute	Phase 1/2	Recruiting	Sichuan University	China
Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma NCT07093710 · ClinicalTrials.gov ↗ · Peripheral T Cell Lymphoma	Phase 1/2	Recruiting	Sun Yat-sen University	China
Golidocitinib and Chidamide for Cutaneous T-Cell Lymphoma NCT07754890 · ClinicalTrials.gov ↗ · Cutaneous T-cell Lymphoma (CTCL)	Phase 1/2	Recruiting	Peking Union Medical College Hospital	China
Re-radiotherapy Combined With Chidamide for the Treatment of Recurrent Head and Neck Squamous Cell Carcinoma After Radiotherapy NCT07545967 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma HNSCC	Phase 1	Recruiting	West China Hospital	China
A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide. NCT05967949 · ClinicalTrials.gov ↗ · PTCL	Observational	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia NCT06386302 · ClinicalTrials.gov ↗ · AML, Acute Myeloid Leukemia	Not applicable	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Chidamide Combined With Brentuximab Vedotin Regimen for CD30+ PTCL Patients NCT07074457 · ClinicalTrials.gov ↗ · CD30+ Peripheral T-cell Lymphoma	Not applicable	Recruiting	The First Affiliated Hospital of Soochow University	China
An Open-label, Single-arm, Multicenter Phase II Clinical Study of Azacitidine, Chidamide Combined With PD-1 Monoclonal Antibody in the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma. NCT07598578 · ClinicalTrials.gov ↗ · Peripheral T-Cell Lymphoma Refractory	Early Phase 1	Recruiting	Second Affiliated Hospital of Soochow University	China
Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor NCT06556862 · ClinicalTrials.gov ↗ · HR+/HER2- Advanced Breast Cancer	Phase 2	Not yet open	Beijing 302 Hospital	China
Chidamide+Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant. NCT06563778 · ClinicalTrials.gov ↗ · Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma	Phase 2	Not yet open	Chinese PLA General Hospital	China
A Prospective, Randomized, Open, Phase II Clinical Study of Chidamide in Combination with Camrelizumab and Apatinib for Advanced Esophageal Cancer NCT06745193 · ClinicalTrials.gov ↗ · Advanced Esophageal Carcinoma	Phase 2	Not yet open	Peking University	China
Chidamide Monotherapy for Intermediate-to-High-Risk Myelodysplastic Syndromes NCT07616336 · ClinicalTrials.gov ↗ · Myelodysplastic Syndromes	Phase 2	Not yet open	Zhongshan Hospital (Xiamen), Fudan University	China
The Efficacy of CAPCT in Patients With PTCL NCT07746245 · ClinicalTrials.gov ↗ · Peripheral T-Cell Lymphoma	Phase 2	Not yet open	The First Affiliated Hospital with Nanjing Medical University	China
Chidamide Combined With Benmelstobart, Nab-paclitaxel, and SBRT as Second-Line Treatment for Advanced BTC NCT07890506 · ClinicalTrials.gov ↗ · BTC	Phase 2	Not yet open	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	China
Prophylactic Strategies for Mitigating Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma NCT07917624 · ClinicalTrials.gov ↗ · Diffuse Large B-Cell Lymphoma (DLBCL)	Phase 2	Not yet open	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
A Safety and Efficacy Trial of Chidamide Combined With NKG2D CAR-NK Cell Therapy for Reducing the HIV Viral Reservoir NCT07577986 · ClinicalTrials.gov ↗ · HIV (Human Immunodeficiency Virus)	Phase 1/2	Not yet open	First Affiliated Hospital of Zhejiang University	China
Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma NCT07601607 · ClinicalTrials.gov ↗ · Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)	Phase 1/2	Not yet open	Sun Yat-sen University	China
AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH NCT05678933 · ClinicalTrials.gov ↗ · Peripheral T-cell Lymphoma Targeted Therapy	Phase 3	By invitation	Tianjin Medical University Cancer Institute and Hospital	China
Evaluating the Efficacy of Chidamide in the Treatment of Initial Unresectable Metastatic Colorectal Cancer With High Expression of SULF1 NCT07927049 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 2/3	By invitation	Sir Run Run Shaw Hospital	China
Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL NCT04668690 · ClinicalTrials.gov ↗ · Peripheral T Cell Lymphoma	Phase 3	Active, closed	CSPC ZhongQi Pharmaceutical Technology Co., Ltd	China
Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma NCT04674683 · Unresectable or Metastatic Melanoma, Progressive Brain Metastasis	Phase 3	Active, closed	HUYABIO International, LLC	UK, USA, Germany, France, Spain, Italy, Belgium, Austria, Czechia, Brazil, Japan, South Korea, Singapore, Australia
A Clinical Study Assessing the Efficacy of Chidamide for CD30-positive Peripheral T-cell Lymphoma (PTCL). NCT06550336 · ClinicalTrials.gov ↗ · Peripheral T Cell Lymphoma	Phase 2	Active, closed	The First Hospital of Jilin University	China
Efficacy and Safety of Chidamide in CBF Leukemia NCT03031262 · ClinicalTrials.gov ↗ · AML	Phase 1/2	Active, closed	Institute of Hematology & Blood Diseases Hospital, China	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Conditions studied with Chidamide

66 conditions

Peripheral T Cell Lymphoma6 Diffuse Large B-Cell Lymphoma (DLBCL)4 Acute Myeloid Leukemia4 AML2 Leukemia, Myeloid, Acute2Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma2Colorectal Cancer2 Diffuse Large B-Cell Lymphoma2HR+/HER2- Advanced Breast Cancer2Unresectable or Metastatic Melanoma1Progressive Brain Metastasis1Relapsed or Refractory Peripheral T-cell Lymphoma1

All 66 conditions

Condition (as registered)	Trials
Peripheral T Cell Lymphoma	6
Diffuse Large B-Cell Lymphoma (DLBCL)	4
Acute Myeloid Leukemia	4
AML	2
Leukemia, Myeloid, Acute	2
Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma	2
Colorectal Cancer	2
Diffuse Large B-Cell Lymphoma	2
HR+/HER2- Advanced Breast Cancer	2
Unresectable or Metastatic Melanoma	1
Progressive Brain Metastasis	1
Relapsed or Refractory Peripheral T-cell Lymphoma	1
Peripheral T-Cell Lymphoma Refractory	1
Acute Monocytic Leukemia	1
Newly Diagnosed	1
Neuroblastoma (NB)	1
Neuroblastoma in Children	1
First Line Therapy	1
Adult T-cell Leukemia/Lymphoma	1
Peripheral T-cell Lymphoma	1
Epigenetic Repression	1
Colon Adenocarcinoma	1
Relapsed Peripheral T-Cell Lymphoma	1
Refractory T-Cell Lymphoma	1
Non-Small Cell Lung Cancer	1
HIV (Human Immunodeficiency Virus)	1
Relapsed/Refractory Acute Myeloid Leukemia	1
PTCL	1
Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)	1
Head and Neck Squamous Cell Carcinoma HNSCC	1
Chidamide	1
R-CHOP Chemotherapy	1
DLBCL - Diffuse Large B Cell Lymphoma	1
Double-expressor Lymphoma (DEL)	1
Diffuse Large B-Cell Lymphoma-Recurrent	1
Diffuse Large B-Cell Lymphoma-Refractory	1
Multiple Myeloma	1
Metastatic Colorectal Cancer	1
Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)	1
Peripheral T-Cell Lymphoma	1
Peripheral Blood Stem Cell Transplantation	1
Myelodysplastic Syndromes	1
Solid Tumor	1
Precision Medicine	1
Colorectal Cancer Metastatic	1
Peripheral T-cell Lymphoma Targeted Therapy	1
Allogeneic Hematopoietic Cell Transplantation (HCT)	1
AML (Acute Myeloid Leukemia)	1
BTC	1
DLBCL	1
APL	1
Targeted Therapy	1
Cutaneous T-cell Lymphoma (CTCL)	1
Natural Killer/T-cell Lymphoma	1
CD30+ Peripheral T-cell Lymphoma	1
Double Expressor DLBCL	1
ELDERLY PEOPLE	1
Unfit, New-diagnosis DLBCL	1
Advanced Esophageal Carcinoma	1
Newly Diagnosed Acute Myeloid Leukemia (AML)	1
Elderly Patients	1
Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy	1
Metastatic Pancreatic Cancer	1
Follicular Lymphoma	1
Refractory B-Cell Lymphoma	1
Relapsed Non-Hodgkin Lymphoma	1

By country register

Register	Trials	Recruiting
Clinical trials in China	60	46
Clinical trials in Taiwan	2	2
Clinical trials in UK	1	0
Clinical trials in USA	1	0
Clinical trials in Germany	1	0
Clinical trials in France	1	0
Clinical trials in Spain	1	0
Clinical trials in Italy	1	0
Clinical trials in Belgium	1	0
Clinical trials in Austria	1	0
Clinical trials in Czechia	1	0
Clinical trials in Brazil	1	0
Clinical trials in Japan	1	0
Clinical trials in South Korea	1	0
Clinical trials in Singapore	1	0
Clinical trials in Australia	1	0

A trial with sites in more than one country appears in each of those registers.

Related compounds

Questions about Chidamide trials

How many clinical trials are testing Chidamide?

62 current trials in our China, Taiwan, UK, USA, Germany, France, Spain, Italy, Belgium, Austria, Czechia, Brazil, Japan, South Korea, Singapore and Australia registers name Chidamide (also registered as HBI-8000) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.

Are Chidamide trials recruiting patients?

Yes. 47 of the 62 trials are recruiting: 46 with sites in China and 2 with sites in Taiwan. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Chidamide clinical trials?

Chinese PLA General Hospital (6), The First Affiliated Hospital of Soochow University (5), Tianjin Medical University Cancer Institute and Hospital (5) and Institute of Hematology & Blood Diseases Hospital, China (4), among 36 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Chidamide works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Chidamide works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Chidamide (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.